Safety of Nintedanib in a Patient with Chronic Pulmonary Fibrosis and Kidney Disease
Safety of Nintedanib in a Patient with Chronic Pulmonary Fibrosis and Kidney Disease
About this item
Full title
Author / Creator
Publisher
Switzerland: MDPI AG
Journal title
Language
English
Formats
Publication information
Publisher
Switzerland: MDPI AG
Subjects
More information
Scope and Contents
Contents
Nintedanib, an intracellular inhibitor that targets multiple tyrosine kinase, is an important drug for the treatment of pulmonary fibrosis. Until now, no studies have been published reporting the nintedanib tolerability or its efficacy in patients with chronic pulmonary lung disease and chronic kidney disease comorbidity. The safety, efficacy and p...
Alternative Titles
Full title
Safety of Nintedanib in a Patient with Chronic Pulmonary Fibrosis and Kidney Disease
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_0404705603c74d069e96ff5f30cf2d09
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_0404705603c74d069e96ff5f30cf2d09
Other Identifiers
ISSN
1424-8247
E-ISSN
1424-8247
DOI
10.3390/ph17091147
